1. Home
  2. PHAR vs VREX Comparison

PHAR vs VREX Comparison

Compare PHAR & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • VREX
  • Stock Information
  • Founded
  • PHAR 1988
  • VREX 2016
  • Country
  • PHAR Netherlands
  • VREX United States
  • Employees
  • PHAR N/A
  • VREX N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • VREX Industrial Machinery/Components
  • Sector
  • PHAR Health Care
  • VREX Technology
  • Exchange
  • PHAR Nasdaq
  • VREX Nasdaq
  • Market Cap
  • PHAR 951.7M
  • VREX 483.7M
  • IPO Year
  • PHAR N/A
  • VREX N/A
  • Fundamental
  • Price
  • PHAR $14.60
  • VREX $11.60
  • Analyst Decision
  • PHAR Strong Buy
  • VREX Strong Buy
  • Analyst Count
  • PHAR 3
  • VREX 2
  • Target Price
  • PHAR $30.00
  • VREX $19.50
  • AVG Volume (30 Days)
  • PHAR 12.7K
  • VREX 336.5K
  • Earning Date
  • PHAR 10-23-2025
  • VREX 08-07-2025
  • Dividend Yield
  • PHAR N/A
  • VREX N/A
  • EPS Growth
  • PHAR N/A
  • VREX N/A
  • EPS
  • PHAR N/A
  • VREX N/A
  • Revenue
  • PHAR $339,836,000.00
  • VREX $821,400,000.00
  • Revenue This Year
  • PHAR $16.63
  • VREX $5.01
  • Revenue Next Year
  • PHAR $6.77
  • VREX $2.97
  • P/E Ratio
  • PHAR N/A
  • VREX N/A
  • Revenue Growth
  • PHAR 22.44
  • VREX N/A
  • 52 Week Low
  • PHAR $7.31
  • VREX $6.76
  • 52 Week High
  • PHAR $17.08
  • VREX $16.93
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 56.71
  • VREX 61.49
  • Support Level
  • PHAR $13.63
  • VREX $10.85
  • Resistance Level
  • PHAR $15.27
  • VREX $11.74
  • Average True Range (ATR)
  • PHAR 0.96
  • VREX 0.48
  • MACD
  • PHAR -0.13
  • VREX -0.11
  • Stochastic Oscillator
  • PHAR 51.83
  • VREX 69.83

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About VREX Varex Imaging Corporation

Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.

Share on Social Networks: